I think when you consider a similar small biotech such as...

I think when you consider a similar small biotech such as Clinuvel (cuv) market cap $1.3 billion you can get an insight into ANPs potential future. Both companies targeted rare diseases in order to get the drugs approved. CUVs drug is approved by EMA and FDA and they are currently looking at further indications. Their drug treats EPP which is not as prevalent as DMD. It's a possible model that ANP may emulate. As many others have stated DMD is the gateway. From there, more mainstream/wide spread diseases could potentially be targeted.

ANP at a market cap a bit over 100 million dollars looks incredibly cheap just for DMD let alone any further uses for the drug.